CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
about
Optimization of the bacterial cytochrome P450 BM3 system for the production of human drug metabolitesSimultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic modelIndividualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.Human liver expression of CYP2C8: gender, age, and genotype effects.Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.Cytochrome P450 2C8 pharmacogenetics: a review of clinical studiesThe CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjectsLack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.Ultra rapidly dissolving repaglinide nanosized crystals prepared via bottom-up and top-down approach: influence of food on pharmacokinetics behavior.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes.Monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm.Cytochrome P450 reaction-phenotyping: an industrial perspective.Pharmacogenetics of glucose-lowering drug treatment: a systematic review.The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.Pharmacogenetics of oral antidiabetic drugs.Pharmacogenetics and personalized treatment of type 2 diabetesQSAR of cytochrome inhibitors.Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population.LC-SPE-NMR-MS: a total analysis system for bioanalysis.Modeling and predicting drug pharmacokinetics in patients with renal impairment.Role of transporters in drug interactions.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.Transporter-mediated drug-drug interactions with oral antidiabetic drugs.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Dealing with the complex drug-drug interactions: towards mechanistic models.Pharmacogenomics of glinides.Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism
P2860
Q27027286-9F76B71A-5A4E-4596-98C7-6CE924AF89EDQ30511951-C19CE77E-2182-4532-A6E1-1144ED4E27A2Q30571118-B475EEE1-EDD0-4CE0-81F0-B2AE53C71D6AQ30776360-1F4051B1-2D4B-4597-AAF8-4E3E5AB144AEQ33891033-7B906315-02B8-4B80-B790-767B3FDDFB6CQ33993320-00E11A28-E094-4621-AE66-6F9C81FA9311Q34561039-4A5688C8-B009-41D5-97D5-DE6237E4FAA5Q35003605-CE1231BE-EBB6-4C52-BDB3-7A5A8AD5C8F1Q35826014-8338DFC5-49FC-4EBB-B2F2-7E0435811AB7Q35826433-F8A63E79-6868-42DC-9725-A65D39F9FA84Q35827146-73F6B4DA-99A0-45FC-A74A-F6E7F3E0EDC8Q35827269-283B4312-E0B6-47D6-88C8-C7A6A0E0FC04Q35827353-7019768E-4B0C-4DAA-9E10-1B8ECCE54CC9Q35868308-23792C1A-F229-4424-8CDC-C0DE95251AA0Q35876954-63503326-0B80-442B-86D4-889353521583Q36336051-CBB36DBE-5346-4375-A5EA-7C67CD912427Q36402091-10BBA8BA-A8DD-42D6-8488-A1A0A12673FEQ36960539-AD945515-D189-4859-8140-511B92AD1369Q36982648-57D26B9A-18AA-43AF-8BD4-1FF5CB3F9FBAQ37175829-6EFF386D-CD81-4236-95E3-A508B2DEBACDQ37353476-704BB789-040B-4DA5-83D5-F054441E3ED6Q37508445-5FDDA2B9-FC90-4A91-8052-9CD61A6F972FQ37587216-77D7AE64-C007-41DC-A247-A8B83FBF8739Q37631831-B9410AB7-0481-4B29-AD59-9DBDA3C1AC2EQ37729214-D599F682-BD8E-40F5-A7AC-184511DBDF7DQ37810187-53FE1BBD-93BC-4D62-BA45-B6887F153FAFQ37960638-1DD8C0DB-B3FC-4669-BDE8-9B41FA439C0DQ37964577-F269C72C-F908-4E5D-A105-499F4A2D8CE0Q38087695-F647C9D9-5398-4D8B-8BA8-307D707278E5Q38130410-49C32455-5535-41AD-AEB2-67CDE26D813CQ38168993-E994CFE3-D4EE-4B27-8328-40FA3FCD6CBEQ38233298-9BE1DA7F-4D0A-40AD-AF3A-C7B7F0E6C756Q38302225-6271BC20-0F2C-46F7-AD7A-5B90A08B719BQ38307994-633CF194-989B-43BF-83D7-B4EF3F540716Q38365410-F16141D8-74C0-4930-8B34-27FA8A9C53A6Q38684505-74C46281-6275-4118-AC51-2756963C5688Q38933872-6F630A74-B4E4-4CFE-90EE-815E5F99D971Q39212609-012C3303-2003-4E89-854B-1C5A4051C29FQ39419233-FE39F240-351B-4147-A8FE-343ECBA8026DQ41589503-7B442018-DC7E-49C1-8108-6B2C534792DC
P2860
CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
CYP2C8 and CYP3A4 are the prin ...... ulin secretagogue repaglinide.
@en
type
label
CYP2C8 and CYP3A4 are the prin ...... ulin secretagogue repaglinide.
@en
prefLabel
CYP2C8 and CYP3A4 are the prin ...... ulin secretagogue repaglinide.
@en
P2093
P2860
P1476
CYP2C8 and CYP3A4 are the prin ...... ulin secretagogue repaglinide.
@en
P2093
Inga Bjørnsdottir
Kristian Tage Hansen
Mikael Søndergård Thomsen
Tanja Busk Bidstrup
Ulla Grove Sidelmann
P2860
P304
P356
10.1046/J.0306-5251.2003.01862.X
P407
P577
2003-09-01T00:00:00Z